Recursion Pharmaceuticals, Inc. $RXRX Shares Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC boosted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 537.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 818,316 shares of the company’s stock after purchasing an additional 689,903 shares during the quarter. Hsbc Holdings PLC’s holdings in Recursion Pharmaceuticals were worth $3,367,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in Recursion Pharmaceuticals by 18.6% in the fourth quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock valued at $192,998,000 after purchasing an additional 7,407,606 shares during the period. State Street Corp boosted its stake in shares of Recursion Pharmaceuticals by 38.7% during the fourth quarter. State Street Corp now owns 25,333,888 shares of the company’s stock worth $103,616,000 after buying an additional 7,064,963 shares during the period. Norges Bank purchased a new position in shares of Recursion Pharmaceuticals during the fourth quarter worth about $23,473,000. ARK Investment Management LLC grew its holdings in shares of Recursion Pharmaceuticals by 11.2% during the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock worth $152,626,000 after buying an additional 3,771,357 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Recursion Pharmaceuticals in the 4th quarter valued at about $6,118,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analyst Ratings Changes

RXRX has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. JPMorgan Chase & Co. dropped their target price on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Morgan Stanley upped their price target on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. Wall Street Zen downgraded Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of “Hold” and an average target price of $8.10.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock opened at $3.52 on Monday. The business’s fifty day moving average price is $3.30 and its 200 day moving average price is $3.69. The firm has a market capitalization of $1.87 billion, a PE ratio of -2.93 and a beta of 1.04. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.47 and a quick ratio of 5.47. Recursion Pharmaceuticals, Inc. has a 1-year low of $2.77 and a 1-year high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The company had revenue of $6.47 million during the quarter, compared to the consensus estimate of $15.78 million. During the same quarter last year, the company earned ($0.50) earnings per share. Recursion Pharmaceuticals’s quarterly revenue was down 56.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.99 EPS for the current fiscal year.

Insider Activity

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 23,588 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $3.58, for a total transaction of $84,445.04. Following the transaction, the chief executive officer directly owned 2,175,796 shares in the company, valued at approximately $7,789,349.68. This represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 30,000 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $3.68, for a total transaction of $110,400.00. Following the completion of the transaction, the director directly owned 6,169,863 shares of the company’s stock, valued at approximately $22,705,095.84. This trade represents a 0.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 121,937 shares of company stock valued at $421,574 in the last quarter. Company insiders own 6.65% of the company’s stock.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.